Pacific Biosciences (PACB) Revenue by Segment

Separates revenue into instruments, consumables, services, and other lines to show which parts of PacBio’s business drive growth and margins. A higher share of consumables and services indicates steadier, recurring income; heavy instrument reliance can mean lumpy quarterly results.

Consumables have clearly become PacBio’s growth engine, delivering consecutive record quarters and rising clinical adoption — shifting revenue mix toward higher‑frequency, pull‑through dollars that underpin Revio economics. By contrast, instrument revenue is volatile, pressured by Vega promotions, ASP normalization and region-specific demand weakness, making hardware a near‑term swing factor. SPRQ-Nx commercialization and Revio traction could reaccelerate consumable growth, but the modest downward guidance and rising compute/memory costs mean margin recovery and timing remain cautious.